-
Infectious Disease Clinics of North... Jun 2015Babesiosis is caused by intraerythrocytic protozoan parasites that are transmitted by ticks, or less commonly through blood transfusion or transplacentally. Human... (Review)
Review
Babesiosis is caused by intraerythrocytic protozoan parasites that are transmitted by ticks, or less commonly through blood transfusion or transplacentally. Human babesiosis was first recognized in a splenectomized patient in Europe but most cases have been reported from the northeastern and upper midwestern United States in people with an intact spleen and no history of immune impairment. Cases are reported in Asia, Africa, Australia, Europe, and South America. Babesiosis shares many clinical features with malaria and can be fatal, particularly in the elderly and the immunocompromised.
Topics: Anti-Bacterial Agents; Babesia; Babesiosis; DNA, Protozoan; Enzyme Inhibitors; Erythrocytes; Humans; Polymerase Chain Reaction
PubMed: 25999229
DOI: 10.1016/j.idc.2015.02.008 -
Parasites & Vectors Jun 2016Canine babesiosis is a significant tick-borne disease caused by various species of the protozoan genus Babesia. Although it occurs worldwide, data relating to European... (Review)
Review
Canine babesiosis is a significant tick-borne disease caused by various species of the protozoan genus Babesia. Although it occurs worldwide, data relating to European infections have now been collected for many years. These data have boosted the publication record and increased our working knowledge of these protozoan parasites. Both the large and small forms of Babesia species (B. canis, B. vogeli, B. gibsoni, and B. microti-like isolates also referred to as "B. vulpes" and "Theileria annae") infect dogs in Europe, and their geographical distribution, transmission, clinical signs, treatment, and prognosis vary widely for each species. The goal of this review is to provide veterinary practitioners with practical guidelines for the diagnosis, treatment and prevention of babesiosis in European dogs. Our hope is that these guidelines will answer the most frequently asked questions posed by veterinary practitioners.
Topics: Animals; Babesia; Babesiosis; Dog Diseases; Dogs; Europe
PubMed: 27289223
DOI: 10.1186/s13071-016-1596-0 -
Veterinary Parasitology Apr 2018Canine babesiosis is a tick-borne disease caused by several Babesia spp. which have different susceptebility to anti-protozoal drugs. A few drugs and drug combinations... (Review)
Review
Canine babesiosis is a tick-borne disease caused by several Babesia spp. which have different susceptebility to anti-protozoal drugs. A few drugs and drug combinations are used in the treatment of canine babesiosis often without complete parasite elimination leaving treated dogs as carriers which could relapse with clinical disease and also transmit infection further. Although the large form canine babesial species Babesia canis, Babesia vogeli and Babesia rossi are sensitive to the aromatic diamidines imidocarb dipropionate and diminazene aceturate, small form species such as Babesia gibsoni, Babesia conradae and Babesia vulpes (Theileria annae) are relatively resistant to these drugs and are treated with the combination of the hydroxynaphthoquinone atovaquone and the antibiotic azithromycin. Azithromycin and other antibiotics that have anti-protozoal properties target the apicoplast, a relict plastid found in protozoa, and exert a delayed death effect. The triple combination of clindamycin, diminazene aceturate and imidocarb dipropionate is also effective against B. gibsoni and used to treat atovaquone-resistant strains of this species. Novel drugs and the synergistic effects of drug combinations against Babesia infection should be explored further to find new treatments for canine babesiosis.
Topics: Animals; Antiprotozoal Agents; Babesia; Babesiosis; Dog Diseases; Dogs
PubMed: 29657012
DOI: 10.1016/j.vetpar.2018.03.001 -
JAMA Apr 2016Lyme disease, human granulocytic anaplasmosis (HGA), and babesiosis are emerging tick-borne infections. (Review)
Review
IMPORTANCE
Lyme disease, human granulocytic anaplasmosis (HGA), and babesiosis are emerging tick-borne infections.
OBJECTIVE
To provide an update on diagnosis, treatment, and prevention of tick-borne infections.
EVIDENCE REVIEW
Search of PubMed and Scopus for articles on diagnosis, treatment, and prevention of tick-borne infections published in English from January 2005 through December 2015.
FINDINGS
The search yielded 3550 articles for diagnosis and treatment and 752 articles for prevention. Of these articles, 361 were reviewed in depth. Evidence supports the use of US Food and Drug Administration-approved serologic tests, such as an enzyme immunoassay (EIA), followed by Western blot testing, to diagnose extracutaneous manifestations of Lyme disease. Microscopy and polymerase chain reaction assay of blood specimens are used to diagnose active HGA and babesiosis. The efficacy of oral doxycycline, amoxicillin, and cefuroxime axetil for treating Lyme disease has been established in multiple trials. Ceftriaxone is recommended when parenteral antibiotic therapy is recommended. Multiple trials have shown efficacy for a 10-day course of oral doxycycline for treatment of erythema migrans and for a 14-day course for treatment of early neurologic Lyme disease in ambulatory patients. Evidence indicates that a 10-day course of oral doxycycline is effective for HGA and that a 7- to 10-day course of azithromycin plus atovaquone is effective for mild babesiosis. Based on multiple case reports, a 7- to 10-day course of clindamycin plus quinine is often used to treat severe babesiosis. A recent study supports a minimum of 6 weeks of antibiotics for highly immunocompromised patients with babesiosis, with no parasites detected on blood smear for at least the final 2 weeks of treatment.
CONCLUSIONS AND RELEVANCE
Evidence is evolving regarding the diagnosis, treatment, and prevention of Lyme disease, HGA, and babesiosis. Recent evidence supports treating patients with erythema migrans for no longer than 10 days when doxycycline is used and prescription of a 14-day course of oral doxycycline for early neurologic Lyme disease in ambulatory patients. The duration of antimicrobial therapy for babesiosis in severely immunocompromised patients should be extended to 6 weeks or longer.
Topics: Amoxicillin; Anaplasma; Anaplasmosis; Animals; Anti-Bacterial Agents; Babesiosis; Blotting, Western; Cefuroxime; Clindamycin; Doxycycline; Drug Administration Schedule; Humans; Immunoenzyme Techniques; Lyme Disease; Microscopy; Neutrophils; Polymerase Chain Reaction; Quinine
PubMed: 27115378
DOI: 10.1001/jama.2016.2884 -
Revue Scientifique Et Technique... Aug 2015Babesiosis is the disease caused by infection of the erythrocytes of mammals by Babesia species, which are Apicomplexa protozoa belonging to the suborder Piroplasmidea... (Review)
Review
Babesiosis is the disease caused by infection of the erythrocytes of mammals by Babesia species, which are Apicomplexa protozoa belonging to the suborder Piroplasmidea and the family Babesiidae. They are different from the Theileriidae, which can also infect white blood cells and endothelial cells. Babesiosis is one of the most important tick-borne infectious diseases of domestic and wild mammals and still poses significant diagnostic and therapeutic challenges for veterinary practitioners around the world. It is an increasing problem worldwide because of the expansion of tick habitats and the increased mobility of animals, which promote the spread of parasites into new geographical areas. Babesia species can, exceptionally, infect humans, especially splenectomised or immunocompromised individuals. The majority of human cases involve B. microti, a parasite of rodents, but human infections may also be caused by B. divergens, which infects cattle, or by Babesia related to B. odocoilei, which infect cervids. The majority of new developments, in regard to taxonomy, epidemiology, pathogenesis and control, concern canine babesiosis, whereas piroplasmosis in horses or cattle retains the classical description, therefore the focus of this article will be on infection in dogs.
Topics: Animals; Babesia; Babesiosis; Europe; Humans
PubMed: 26601462
DOI: 10.20506/rst.34.2.2385 -
Archives of Pathology & Laboratory... Jan 2019Babesiosis is most commonly caused by Babesia microti and is transmitted via the bite of an infected Ixodes spp tick. However, Babesia is also transmitted via blood...
Babesiosis is most commonly caused by Babesia microti and is transmitted via the bite of an infected Ixodes spp tick. However, Babesia is also transmitted via blood transfusion. In the United States, the first case of transfusion-transmitted babesiosis was recognized in 1979, and in recent years, the incidence has rapidly increased. Because most of the infected blood donors do not experience any symptoms, they pose a significant risk to the blood supply. Donor deferral for a history of babesiosis is currently performed but is ineffective. In March 2018, the FDA licensed a DNA PCR and antibody assay that were used in tandem in pivotal trials for screening blood donors for B microti; with other assays still being evaluated under investigational new drug protocols. Blood donation screening is essential to reducing the risk of transfusion-transmitted babesiosis, which is why blood centers collecting in geographic regions of highest risk have been testing since approximately 2010. Investigational NAT assays of higher sensitivity are pending FDA review. Further, in July 2018, the FDA issued a draft guidance for reducing the risk of transfusion-transmitted babesiosis. Release of the final guidance may be postponed until sensitivities and specificities of all current and potential strategies have been properly evaluated.
Topics: Babesiosis; Blood Donors; Cost-Benefit Analysis; Donor Selection; Erythrocytes; Humans; Transfusion Reaction
PubMed: 30376376
DOI: 10.5858/arpa.2017-0250-RS -
Przeglad Epidemiologiczny 2015Babesiosis is an emerging parasitic, anthropo-zoonotic tick-borne disease, seldom diagnosed in humans. Caused by Protozoa, Babesia (also called Piroplasma)... (Review)
Review
Babesiosis is an emerging parasitic, anthropo-zoonotic tick-borne disease, seldom diagnosed in humans. Caused by Protozoa, Babesia (also called Piroplasma) intraerytrocytic piriform microorganism. Infection of vertebrates is transmitted by ticks. Out of more than 100 Babesia species/genotypes described so far, only some were diagnosed in infected humans, mostly B. microti, B. divergens and B. venatorum (Babesia sp. EU1). Infection in humans is often asymptomatic or mild but is of a particular risk for asplenic individuals, those with congenital or acquired immunodeficiencies, and elderly. Infections transmitted with blood and blood products raise concerns in hemotherapy. Epidemiological situation of babesiosis varies around the world. In Europe, no increase in the number of cases was reported, but in the USA its prevalence is increasing and extension of endemic areas is observed. The aim of this publication is to describe the problems connected with the current epidemiological situation, diagnosis and treatment of human babesiosis with regard to clinical status of patients.
Topics: Animals; Babesia; Babesiosis; Communicable Diseases, Emerging; Europe; Humans; Poland; Zoonoses
PubMed: 26519845
DOI: No ID Found -
CMAJ : Canadian Medical Association... Oct 2021
Topics: Aged; Animals; Anti-Bacterial Agents; Babesia microti; Babesiosis; Host-Parasite Interactions; Humans; Lyme Disease; Male
PubMed: 34663609
DOI: 10.1503/cmaj.201983-f -
Clinical Infectious Diseases : An... Feb 2023Human babesiosis is a worldwide emerging tick-borne disease caused by intraerythrocytic protozoa. Most patients experience mild to moderate illness, but life-threatening...
BACKGROUND
Human babesiosis is a worldwide emerging tick-borne disease caused by intraerythrocytic protozoa. Most patients experience mild to moderate illness, but life-threatening complications can occur. Although cardiac complications are common, the full spectrum of cardiac disease and the frequency, risk factors, and outcomes in patients experiencing cardiac complications are unclear. Accordingly, we carried out a record review of cardiac complications among patients with babesiosis admitted to Yale-New Haven Hospital over the last decade to better characterize cardiac complications of babesiosis.
METHODS
We reviewed the medical records of all adult patients with babesiosis admitted to Yale-New Haven Hospital from January 2011 to October 2021, confirmed by identification of Babesia parasites on thin blood smear and/or by polymerase chain reaction. The presence of Lyme disease and other tick-borne disease coinfections were recorded.
RESULTS
Of 163 enrolled patients, 32 (19.6%) had ≥1 cardiac complication during hospitalization. The most common cardiac complications were atrial fibrillation (9.4%), heart failure (8.6%), corrected QT interval prolongation (8.0%), and cardiac ischemia (6.8%). Neither cardiovascular disease risk factors nor preexisting cardiac conditions were significantly associated with the development of cardiac complications. The cardiac complication group had a greater prevalence of high-grade parasitemia (>10%) (P < .001), longer median length of both hospital (P < .001) and intensive care unit stay (P < .001), and a higher mortality rate (P = .02) than the group without cardiac complications.
CONCLUSIONS
Cardiac complications of acute babesiosis are common and occurred in approximately one-fifth of this inpatient sample. Further investigation is needed to elucidate the relationship between babesiosis severity and cardiac outcomes.
Topics: Adult; Humans; Babesia microti; Babesiosis; Heart Diseases; Lyme Disease; Tick-Borne Diseases
PubMed: 35983604
DOI: 10.1093/cid/ciac525 -
PloS One 2019Babesiosis is a parasitic vector-borne disease of increasing public health importance. Since the first human case was reported in 1957, zoonotic species have been... (Review)
Review
BACKGROUND
Babesiosis is a parasitic vector-borne disease of increasing public health importance. Since the first human case was reported in 1957, zoonotic species have been reported on nearly every continent. Zoonotic Babesia is vectored by Ixodes ticks and is commonly transmitted in North America by Ixodes scapularis, the tick species responsible for transmitting the pathogens that also cause Lyme disease, Powassan virus, and anaplasmosis in humans. Predicted climate change is expected to impact the spread of vectors, which is likely to affect the distribution of vector-borne diseases including human babesiosis.
METHODS
A scoping review has been executed to characterize the global evidence on zoonotic babesiosis. Articles were compiled through a comprehensive search of relevant bibliographic databases and targeted government websites. Two reviewers screened titles and abstracts for relevance and characterized full-text articles using a relevance screening and data characterization tool developed a priori.
RESULTS
This review included 1394 articles relevant to human babesiosis and/or zoonotic Babesia species. The main zoonotic species were B. microti, B. divergens, B. duncani and B. venatorum. Articles described a variety of study designs used to study babesiosis in humans and/or zoonotic Babesia species in vectors, animal hosts, and in vitro cell cultures. Topics of study included: pathogenesis (680 articles), epidemiology (480), parasite characterization (243), diagnostic test accuracy (98), mitigation (94), treatment (65), transmission (54), surveillance (29), economic analysis (7), and societal knowledge (1). No articles reported predictive models investigating the impact of climate change on Babesia species.
CONCLUSION
Knowledge gaps in the current evidence include research on the economic burden associated with babesiosis, societal knowledge studies, surveillance of Babesia species in vectors and animal hosts, and predictive models on the impact of climate change. The scoping review results describe the current knowledge and knowledge gaps on zoonotic Babesia which can be used to inform future policy and decision making.
Topics: Animals; Babesia; Babesiosis; Climate Change; Cost of Illness; Disease Vectors; Humans; Zoonoses
PubMed: 31887120
DOI: 10.1371/journal.pone.0226781